Catabasis Pharmaceuticals rebrands with new disease focus

Catabasis is aiming to use Quellis’ lead program as the groundwork for what is essentially a new company, focusing on the allergy and immunology space. It has also rebranded, ditching the name "Catabasis" for "Astria Pharmaceuticals."